Alloy Therapeutics Partner with Takeda to Develop Cell Therapy Platform

Alloy Therapeutics Inc. announced a strategic collaboration and licensing agreement with Takeda Pharmaceutical Company to advance its iPSC-derived CAR-T (iCAR-T) and CAR-NK (iCAR-NK) platforms. Developed through Takeda’s T-CiRA research with Kyoto University, iCAR-T technology enables “off-the-shelf” cell therapies with enhanced potency and reduced manufacturing costs. Alloy aims to accelerate therapies targeting solid and blood cancers.

Learn more